Alector, Inc. (ALEC) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 34.24M USD | Liabilities, Current |
| Cash and equivalents | 59.91M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 112.88M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $34.24M | $59.91M | $112.88M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $40.97M | $76.96M | $129.55M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $69.50M | $65.80M | $190.22M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $79.96M | $76.50M | $214.60M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $84.35M | $44.77M | $262.51M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $109.77M | $37.97M | $316.58M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $125.06M | $33.02M | $380.38M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $142.53M | $37.16M | $420.04M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $147.68M | $47.55M | $455.79M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $164.92M | $72.55M | $489.53M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $177.95M | $74.56M | $474.31M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $155.40M | $101.96M | $486.90M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $132.27M | $131.54M | $498.51M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $99.30M | $195.56M | $473.77M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $93.81M | $154.32M | $558.53M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $160.89M | $184.23M | $574.08M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $149.41M | $172.26M | $636.59M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $142.88M | $454.62M | $413.95M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $139.56M | $329.15M | $406.10M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $132.81M | $516.53M | $261.32M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $74.39M | $125.71M | $193.86M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $64.06M | $110.70M | $252.04M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $68.09M | $49.97M | $363.34M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $71.09M | $84.98M | $376.74M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $65.86M | $92.50M | $411.14M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $71.78M | $160.92M | $387.62M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $61.97M | $89.64M | $263.43M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $58.72M | $86.97M | $294.47M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $67.10M | $69.21M | $341.73M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $55.83M | $60.95M | $375.64M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $47.95M | $65.47M | $224.94M | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $41.94M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $48.91M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $37.40M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $32.45M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |